

## BOARD RENEWAL

- **PYC is a clinical-stage drug development company specialising in the creation of precision RNA therapies for patients with genetic diseases who have no treatment options available to them**
- **As part of its Board renewal process, the Company today announces that:**
  - **PYC has appointed Mr. Peter Coleman as its incoming Independent Chair effective immediately after the 2025 Annual General Meeting (AGM); and**
  - **Mr. Alan Tribe will step down from the Board at the conclusion of the upcoming AGM to facilitate Mr. Coleman's appointment**

### **PERTH, Australia and SAN FRANCISCO, California – 13 November 2025**

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

The Company today announces the appointment of Peter Coleman as Independent Non-Executive Chair effective immediately after the Company's Annual General Meeting (AGM) scheduled to occur on Tuesday 18 November 2025.

Mr. Coleman previously served as the CEO of Woodside between 2011 and 2021 and brings deep experience across both commercial and corporate governance domains with particular expertise in corporate and asset-level mergers and acquisitions. These skills will be valuable to the Company in the next phase of its journey.

Mr. Coleman commented *"I am excited to join such an innovative company at this critical stage in its development journey. The potential to demonstrate patient impact over the coming 24 months is going to create multiple commercial options for PYC and I look forward to applying my expertise in this area for the benefit of the Company and its shareholders"*.

To align with long-term shareholder value creation, the Company intends to issue, pursuant to ASX Listing Rule 10.12 exception 12, Mr. Coleman with 2 million unlisted options exercisable at any time before 19 November 2028 at an exercise price of \$1.80 each.

PYC's current Chair, Mr. Alan Tribe, will not seek re-election as a Director at the AGM to facilitate Mr. Coleman's appointment.

The Board extends its gratitude to Mr. Tribe for his stewardship of the Company since taking up the role in 2018. During his tenure, the Company has grown from a basic research laboratory

to a clinical-stage, multi-asset Company with four near-term human efficacy read-outs in areas of major unmet patient need.

As part of the renewal process, Mr. Andrew Taylor has resigned as co-Company Secretary and Chief Financial Officer effective from the end of the AGM. The Board extends its thanks to Mr. Taylor for his contributions to the Company since joining PYC in April 2022.

The Company's longstanding secretary, Mr. Kevin Hart, will resume responsibilities as sole Company Secretary going forward.

## **2025 AGM – Withdrawal of Resolution 2**

Following the change in Chair, the Board has determined to withdraw Resolution 2 from the Notice of Meeting dated 17 October 2025 relating to the 2025 AGM (**2025 NOM**). Resolution 2 related to the re-appointment of Mr. Tribe which is no longer necessary given his decision not to seek re-election at the end of the AGM. The Board considers it appropriate to withdraw this resolution based on Mr. Tribe's decision, rather than proceed with a vote. Accordingly, shareholders are advised that any votes cast on Resolution 2 will be disregarded.

The withdrawal of Resolution 2 will not affect the validity of proxy forms already submitted in respect of the remaining resolutions to be considered at the AGM. All other items of business in the 2025 NOM will proceed as scheduled.

## **About PYC Therapeutics**

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development<sup>1</sup>.

For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#) and [X](#).

## **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

---

<sup>1</sup> Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.2022232>

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited*

## **CONTACT US**

**Investor relations and media contact**

[investor@pyctx.com](mailto:investor@pyctx.com)

